Observational Study; Clinical Effectiveness and Impact on Health-related Quality of Life in Peruvian Patients With Psoriasis After 16 Weeks of Adalimumab Therapy.

Trial Profile

Observational Study; Clinical Effectiveness and Impact on Health-related Quality of Life in Peruvian Patients With Psoriasis After 16 Weeks of Adalimumab Therapy.

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 21 Oct 2014

At a glance

  • Drugs Adalimumab (Primary)
  • Indications Plaque psoriasis
  • Focus Therapeutic Use
  • Sponsors Abbott Laboratories
  • Most Recent Events

    • 28 Jan 2014 According to the ClinicalTrials.gov record, status changed from recruiting to discontinued.
    • 19 Aug 2013 Planned end eate changed from 1 Mar 2014 to 1 Apr 2014 as reported by ClinicalTrials.gov.
    • 16 May 2013 Planned end date changed from 1 Nov 2013 to 1 Mar 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top